| ADOLOR CORPORATION (ADLR)
|" ADOLOR CORPORATION" Graph source Edgar Online Pro on April 21st, 2006
The Following data is sourced from Yahoo Finance & the ANNUAL REPORT ON FORM 10-K for Fiscal Year Ended December 31, 2005 The overview of the company was:
Adolor Corporation, a development stage biopharmaceutical corporation, engages in the discovery, development, and commercialization of prescription pain management products primarily in the United States. It is developing Entereg, a small molecule mu-opioid receptor antagonist intended to selectively block the unwanted effects of opioid analgesics on the gastrointestinal tract. The company’s other products under development include a sterile lidocaine patch, a Phase 2 clinical development product for treating postoperative incisional pain; and Delta opioid agonist, a preclinical development stage product for the treatment of moderate-to-severe pain conditions. Adolor was founded in 1993 and is headquartered in Exton, Pennsylvania.
Highlights of Risks Related to Our (ADLR) Business
For further detail please review the 10 K Form in detail.
1. We are highly dependent on achieving success in the clinical testing, regulatory approval and commercialization of our lead product candidate, Entereg ® , which may never be approved for commercial use.
2. Although we received an approvable letter from the FDA for Entereg ® in POI, our NDA for Entereg ® may not be approved. Study 314 results may not satisfy the FDA requirement for additional evidence of efficacy to support approval of our NDA.
3. Certain results from Phase III clinical trials showed that the differences in the primary endpoint analyses between Entereg ® and placebos were not statistically significant.
4. Unfavorable results or adverse safety findings from any clinical study will adversely affect our ability to obtain regulatory approval for Entereg ® .
5. Entereg ® may not be successfully developed for chronic use.
6. If we are unable to commercialize Entereg ® , our ability to generate revenues will be impaired and our business will be harmed.
7. Patient enrollment may be slow and patients may discontinue their participation in clinical studies, which may negatively impact the results of these studies, and extend the timeline for completion of our and our collaborator’s development programs for our product candidates.
8. We may suffer significant setbacks in advanced clinical trials, even after promising results in earlier trials.
9. Our stock price may be volatile, and your investment in our stock could decline in value.
10. We have been named in a purported class action lawsuit and related derivative lawsuits.
11. If we continue to incur operating losses for a period longer than anticipated, we may be unable to continue our operations.
12. We are dependent on our collaborators to perform their obligations under our collaboration agreements.
13. We have limited commercial manufacturing capability and expertise. If we are unable to contract with third parties to manufacture our products in sufficient quantities, at an acceptable cost and in compliance with regulatory requirements, we may be unable to obtain regulatory approvals, or to meet demand for our products.
14. If we are unable to fully develop sales, marketing and distribution capabilities or enter into agreements with third parties to perform these functions, we will not be able to commercialize products.
15. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approval and depend on third parties to conduct our clinical trials.
16. Our ability to enter into new collaborations and to achieve success under existing collaborations is uncertain.
17. We may not be able to successfully develop in-licensed product candidates, which could prevent us from commercializing any such candidates.
18. Because our product candidates are in development, there is a high risk that further development and testing will demonstrate that our product candidates are not suitable for commercialization.
19. The concept of developing peripherally acting opioid antagonist drugs is relatively new and may not lead to commercially successful drugs.
20. Reduction in the use of opioid analgesics would therefore reduce the potential market for Entereg ® .
21. If competitors develop and market products that are more effective, have fewer side effects, are less expensive than our product candidates or offer other advantages, our commercial opportunities will be limited.
22. Our Delta agonist IND has been put on clinical hold by the FDA.
23. Our business could suffer if we cannot attract, retain and motivate skilled personnel and cultivate key academic collaborations.
24. Companies and universities that have licensed technology and product candidates to us are sophisticated entities that could develop similar products to compete with products we hope to develop.
25. If we breach our licensing agreements, we will lose significant benefits and may be exposed to liability for damages.
26. Because we are not certain we will obtain necessary regulatory approvals to market our products in the United States and foreign jurisdictions, we cannot predict whether or when we will be permitted to commercialize any of our products.
27. If we market products in a manner that violates health care fraud and abuse laws, we may be subject to civil or criminal penalties.
28. The federal Controlled Substances Act might impose significant restrictions, licensing and regulatory requirements on the manufacturing, distribution and dispensing of certain of our product candidates.
29. We may not obtain FDA approval to conduct clinical trials that are necessary to satisfy regulatory requirements.
30. It is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights; we may be sued by others for infringing their intellectual property.
31. Our ability to generate revenues will be diminished if we fail to obtain acceptable prices or an adequate level of reimbursement for our products from third-party payors.
32. If we engage in an acquisition or business combination, we will incur a variety of risks that could adversely affect our business operations or our stockholders.
33. If product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may have to limit or cease commercialization of our products.
34. If we use biological and hazardous materials in a manner that causes injury or violates laws, we may be liable for damages.
35. Certain provisions of our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.
Recent articles on the medical industry:
For New Research Projects Contact The Chairman at Email: firstname.lastname@example.org
Disclaimer of Warranty and Limitation of Liability
products and services on this web site or letter are provided on an "AS IS," "WHERE IS" and "WHERE AVAILABLE" basis.
The KIN Consortium does not warrant the information or services provided herein or your use of this
web site generally, either expressly or impliedly, for any particular purpose and expressly disclaims any implied warranties,
including but not limited to, warranties of title, non-infringement, merchantability or fitness for a particular purpose.
The KIN Consortium will not be responsible for any loss or damage that could result from interception
by third parties of any information or services made available to you via this web site. Although the information provided
to you on this web site is obtained or compiled from sources we believe to be reliable, The KIN Consortium
cannot and does not guarantee the accuracy, validity, timeliness or completeness of any information or data made available
to you for any particular purpose. Neither The KIN Consortium , nor any of its affiliates, directors,
officers or employees, nor any third party vendor, will be liable or have any responsibility of any kind for any loss or damage
that you incur in the event of any failure or interruption of this web site, or resulting from the act or omission of any
other party involved in making this web site, the data contained herein or the products or services offered on this web site
available to you, or from any other cause relating to your access to, inability to access, or use of the web site or these
materials, whether or not the circumstances giving rise to such cause may have been within the control of The KIN
Consortium or of any vendor providing software or services. In no event will The KIN Consortium
or any such parties be liable to you, whether in contract or tort, for any direct, special, indirect, consequential or incidental
damages or any other damages of any kind even if The KIN Consortium or any other such party has been
advised of the possibility thereof. This limitation on liability includes, but is not limited to, the transmission of any
viruses which may infect a user's equipment, failure of mechanical or electronic equipment or communication lines, telephone
or other interconnect problems (e.g., you cannot access your internet service provider), unauthorized access, theft, operator
errors, strikes or other labor problems. The KIN Consortium cannot and does not guarantee continuous,
uninterrupted or secure access to the web site.
All right, title and interest
in this web site and any content contained herein is the exclusive property of The KIN Consortium ,
except as otherwise stated. Unless otherwise specified, this web site is for your personal and non-commercial use only and
you may print, copy and download any information or portion of this web site for your personal use only. You may not modify,
copy, distribute, transmit, display, perform, reproduce, publish, license, frame, create derivative works from, transfer,
or otherwise use in any other way for commercial or public purposes in whole or in part any information, software, products
or services obtained from this web site, except for the purposes expressly provided herein, without The KIN Consortium's prior
written approval. If you copy or download any information or software from this web site, you agree that you will not remove
or obscure any copyright or other notices or legends contained in any such information.
The KIN Consortium and
other trademarks and service marks referenced herein are trademarks and service marks of The KIN Consortium .
The names of other companies and third-party products or services mentioned herein may be the trademarks or service marks
of their respective owners. You are prohibited from using any marks for any purpose including, but not limited to use as metatags
on other pages or sites on the World Wide Web without the written permission of The KIN Consortium
or such third party, which may own the marks.
Pursuant to Section 512(c)(2) of the Copyright Act, The KIN
Consortium designates the following agent to receive notifications of claimed infringement: Khalid I Natto,
The KIN Consortium , Email: email@example.com, Website: http://khalidnatto.tripod.com
Use of Links
This web site contains links
to third party web sites. These links are provided only as a convenience. The inclusion of any link is not and does not imply
an affiliation, sponsorship, endorsement, approval, investigation, verification or monitoring by The KIN Consortium
of any information contained in any third party web site. In no event shall The KIN Consortium be responsible
for the information contained on that site or your use of or inability to use such site. You should also be aware that the